Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026Human reviewedUpdated Aug 2026

Evidence / Men's Hormone Health

CoverageMen's Hormone Health

Does testosterone therapy improve depression or low mood in hypogonadal men?

Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026

Updated Aug 2026·10 studies analyzed·4 core studies·Applies to: hypogonadal men

Bottom line

Some randomized trials and meta-analyses show modest improvements in depressive symptoms among men with low testosterone, but effects are heterogeneous and not a substitute for standard psychiatric evaluation when major depression is present.[1–6]

Evidence confidence

Evidence Confidence

Moderate
LimitedModerateHigh

Relevant evidence exists, but study designs, populations, or conclusions differ enough to keep certainty moderate.

Key uncertainty. Optimal patient selection and duration of benefit are unclear.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

TRT and depression▼

Some randomized trials and meta-analyses show modest improvements in depressive symptoms among men with low testosterone, but effects are heterogeneous and not a substitute for standard psychiatric evaluation when major depression is present.

Testosterone mood symptoms▼

Some randomized trials and meta-analyses show modest improvements in depressive symptoms among men with low testosterone, but effects are heterogeneous and not a substitute for standard psychiatric evaluation when major depression is present.

Can testosterone replacement help men who are depressed?▼

Some randomized trials and meta-analyses show modest improvements in depressive symptoms among men with low testosterone, but effects are heterogeneous and not a substitute for standard psychiatric evaluation when major depression is present.

testosterone help depression mood men▼

Some randomized trials and meta-analyses show modest improvements in depressive symptoms among men with low testosterone, but effects are heterogeneous and not a substitute for standard psychiatric evaluation when major depression is present.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 9 relevant studies.

Overall finding

4 studies address sexual desire, with weighted findings showing benefit. 4 studies address erectile function, with weighted findings showing benefit. 3 studies address sexual activity, with weighted findings showing benefit. 3 studies address bone mineral density, with weighted findings showing no meaningful effect. 6 randomized or systematic-review reports and 3 observational studies address treatment.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Favors treatment

Sexual desire

high · 4 studies

4 studies address sexual desire, with weighted findings showing benefit. This is a patient-reported / subjective outcome.

Patient-reported

Studies

PMID 37589949PMID 27355400PMID 28434676PMID 29150464
Favors treatment

Erectile function

high · 4 studies

4 studies address erectile function, with weighted findings showing benefit.

Mixed measurement

Studies

PMID 37589949PMID 27355400PMID 28434676PMID 29150464
Favors treatment

Sexual activity

high · 3 studies

3 studies address sexual activity, with weighted findings showing benefit. This is a patient-reported / subjective outcome.

Patient-reported

Studies

PMID 37589949PMID 27355400PMID 28434676
No clear effect

Bone mineral density

high · 3 studies

3 studies address bone mineral density, with weighted findings showing no meaningful effect. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 19820017PMID 26901812PMID 11730247
Favors treatment

Mood-related cognitive symptoms

moderate · 2 studies

2 studies address mood-related cognitive symptoms, with weighted findings showing benefit. This is a patient-reported / subjective outcome.

Patient-reported

Studies

PMID 29150464PMID 25873947
Favors treatment

Major adverse cardiovascular events

moderate · 1 study

1 study addresses major adverse cardiovascular events, with weighted findings showing benefit. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 37589949

Magnitude / clinical importance

Validated effect estimates in the analyzed set include mean difference=2.31; or 10. Statistical significance is not the same as clinical importance.

Where quantified, effects were often statistically detectable but small in absolute terms.

Agreement across studies

Most studies agree on sexual desire (benefit), while bone mineral density findings are no meaningful effect and more consistent across domains.

Supports main conclusion: 4 · Neutral / mixed: 5 · Credible conflicting: 0

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • Estrogens primarily regulate bone homeostasis in adult men, and testosterone and estradiol levels must decline substantially to impact the skeleton.
  • It has generally been held that estrogen and testosterone are the major sex steroids regulating bone metabolism in women and men, respectively.
  • Before the characterization of human and animal models of estrogen deficiency, estrogen action was confined in the context of the female bone.

Risks & harms

2 studies report safety-relevant findings. Design mix: Study design not clearly classified, Systematic review / meta-analysis. Rare-event inference should not rest on underpowered trials alone.

Who this applies to

Most studies included hypogonadal men.

What remains uncertain

  • Optimal patient selection and duration of benefit are unclear.
  • Optimal patient selection and duration of benefit are unclear.

Clinical takeaway

Consider testosterone as adjunctive therapy only after appropriate psychiatric evaluation when major depression is present. In hypogonadal men with low mood and confirmed deficiency, a monitored trial may help selected patients but should not replace standard depression treatment.

Favors treatment

Sexual desire?

Benefit

high[37589949 · 27355400 · 28434676 · 29150464]

Favors treatment

Erectile function?

Benefit

high[37589949 · 27355400 · 28434676 · 29150464]

Favors treatment

Sexual activity?

Benefit

high[37589949 · 27355400 · 28434676]

No clear effect

Bone mineral density?

No meaningful effect

high[19820017 · 26901812 · 11730247]

Favors treatment

Mood-related cognitive symptoms?

Benefit

moderate[29150464 · 25873947]

Favors treatment

Major adverse cardiovascular events?

Benefit

moderate[37589949]

No clear effect

Fractures?

No meaningful effect

moderate[19820017]

Favors treatment

Mortality?

Benefit

moderate[29150464]

6 randomized or systematic-review reports and 3 observational studies address treatment. Weighted treatment findings show benefit.

6 RCT / systematic review · 3 observational

Large randomized trials strongly influence the conclusion

4 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

6 supporting studies add context beyond the core evidence base.

Regimen & duration

Observational and supporting studies provide context and do not outrank higher-appropriateness designs.

Long-term uncertainty

Study quality or consistency across available evidence limits certainty.

10 analyzed studies

Strongest evidence

Cureus2026

Landmark studyPMID 41798477

Psychiatric and Cognitive Effects of Testosterone Therapy in Adult Men: A Systematic Review of Clinical Evidence and Mechanistic Insights.

Testosterone plays a critical role in male physical and psychological health, influencing not only reproductive and metabolic functions but also mood, cognition, and overall mental well-being. Age-related testosterone decline has been associated with depressive symptoms, cognitive impairment, and reduced quality of life.

Review
Evidence
Relevance
The Journal of clinical endocrinology and metabolism2016

Landmark studyPMID 27355400

Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels.

In older men with low libido and low T levels, improvements in sexual desire and activity in response to T treatment were related to the magnitude of increases in T and estradiol levels, but there was no clear evidence of a threshold effect.

RCT
Evidence
Relevance
The Journal of clinical endocrinology and metabolism2018

Landmark studyPMID 29562364

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.

We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic tes…

Study
Evidence
Relevance

Supporting literature

Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.

Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels.

Gonadal steroid-dependent effects on bone turnover and bone mineral density in men.

+3 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Men's Hormone Health.

Does testosterone replacement increase cardiovascular risk?

Large randomized data (including TRAVERSE) do not show a significant increase in major adverse cardiovascular events with testosterone therapy in hypogonadal men over median follow-up of roughly three years. Older observational studies conflict, and absolute risk depends on baseline cardiovascular disease, formulation, and monitoring.

11 linked studies

Does testosterone therapy increase prostate cancer risk?

Current systematic reviews and trial secondary analyses do not show a convincing increase in prostate cancer incidence among hypogonadal men treated with testosterone, though surveillance remains standard practice.

14 linked studies

Does testosterone therapy increase hematocrit and polycythemia risk?

Testosterone therapy commonly raises hematocrit; polycythemia is a recognized adverse effect requiring dose adjustment, formulation changes, or phlebotomy when thresholds are exceeded.

14 linked studies

Does testosterone therapy suppress fertility in men?

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and reliably reduces spermatogenesis. Recovery after discontinuation is variable and may be incomplete in some men.

14 linked studies

Go deeper on Men's Hormone Health

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Men's Hormone HealthView pricing